Midazolam hydrochloride is under clinical development by Neuraxpharm France and currently in Phase III for Status Epilepticus. According to GlobalData, Phase III drugs for Status Epilepticus have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Midazolam hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Midazolam hydrochloride overview

Midazolam (Buccolam) is a benzodiazepine derivative acts as anti-epileptic agent.  Buccolam is formulated as a solution for the buccal route of administration. Buccolam is indicated for the treatment of prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents in the patients diagnosed with epilepsy. It is also indicated for the treatment of status epilepticus.

Midazolam (Buccolam/ TAK-815/SHP-615) is under development for the treatment of status epilepticus in the U.S.

For a complete picture of Midazolam hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.